Dennis Hsu

612 total citations
17 papers, 396 citations indexed

About

Dennis Hsu is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Dennis Hsu has authored 17 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 7 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Dennis Hsu's work include Colorectal Cancer Treatments and Studies (4 papers), RNA and protein synthesis mechanisms (4 papers) and RNA modifications and cancer (3 papers). Dennis Hsu is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), RNA and protein synthesis mechanisms (4 papers) and RNA modifications and cancer (3 papers). Dennis Hsu collaborates with scholars based in United States, India and Türkiye. Dennis Hsu's co-authors include Ji Luo, Liam C. Lee, Chih-Shia Lee, Mitali Das, Linda Yan, Edward F. Plow, Hanhan Li, Jun Qin, Sujay Subbayya Ithychanda and Marjan Guček and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Dennis Hsu

17 papers receiving 393 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dennis Hsu United States 9 284 109 68 54 29 17 396
Kalle Ojala Finland 6 236 0.8× 85 0.8× 76 1.1× 48 0.9× 35 1.2× 12 334
María del Mar Maldonado Puerto Rico 7 225 0.8× 91 0.8× 80 1.2× 78 1.4× 41 1.4× 13 335
Frederick D. Park United States 5 227 0.8× 82 0.8× 50 0.7× 38 0.7× 27 0.9× 5 349
Kristen Bisanz United States 6 287 1.0× 124 1.1× 58 0.9× 47 0.9× 37 1.3× 7 389
Edison Tak‐Bun Liu Singapore 7 246 0.9× 117 1.1× 85 1.3× 56 1.0× 26 0.9× 7 363
Francesca Miccichè Italy 9 279 1.0× 147 1.3× 112 1.6× 43 0.8× 30 1.0× 9 360
Weimin Hu United States 8 305 1.1× 188 1.7× 79 1.2× 88 1.6× 54 1.9× 10 431
Yuliya Petrova United States 7 269 0.9× 110 1.0× 62 0.9× 112 2.1× 43 1.5× 9 415
Mary Iconomou Australia 7 310 1.1× 129 1.2× 87 1.3× 47 0.9× 35 1.2× 9 392
Alice Boulghourjian Australia 6 227 0.8× 142 1.3× 154 2.3× 39 0.7× 31 1.1× 6 362

Countries citing papers authored by Dennis Hsu

Since Specialization
Citations

This map shows the geographic impact of Dennis Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dennis Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dennis Hsu more than expected).

Fields of papers citing papers by Dennis Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dennis Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dennis Hsu. The network helps show where Dennis Hsu may publish in the future.

Co-authorship network of co-authors of Dennis Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Dennis Hsu. A scholar is included among the top collaborators of Dennis Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dennis Hsu. Dennis Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Jonassaint, Naudia, John C. Rhee, Dennis Hsu, et al.. (2025). Phase II trial of zanzalintinib (XL-092) in combination with durvalumab and tremelimumab in unresectable hepatocellular carcinoma (ZENOBIA).. Journal of Clinical Oncology. 43(16_suppl). 1 indexed citations
3.
Wu, Xujia, Huairui Yuan, Tingting Duan, et al.. (2024). Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming. Nature Cancer. 5(7). 1024–1044. 15 indexed citations
4.
Yamaguchi, Norihiro, Akimasa Hayashi, Dennis Hsu, et al.. (2024). A Targetable Secreted Neural Protein Drives Pancreatic Cancer Metastatic Colonization and HIF1α Nuclear Retention. Cancer Discovery. 14(12). 2489–2508. 2 indexed citations
5.
Şahin, İbrahim Halil, Turçin Saridogan, Rüveyda Ayasun, et al.. (2024). Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine. JCO Oncology Practice. 20(10). 1336–1347. 7 indexed citations
6.
Hsu, Dennis & Sohail F. Tavazoie. (2024). Cysteine substitutants emerge in lung cancer proteomes during arginine restriction. Molecular Cell. 84(10). 1819–1821. 1 indexed citations
7.
Şahin, İbrahim Halil, et al.. (2023). A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC). Current Oncology. 30(9). 8266–8277. 8 indexed citations
8.
Şahin, İbrahim Halil, Janie Y. Zhang, Turçin Saridogan, et al.. (2023). Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future. JCO Oncology Practice. 19(5). 251–259. 17 indexed citations
9.
Hsu, Dennis, Norihiro Yamaguchi, Alexandra M. Pinzaru, et al.. (2023). Arginine limitation drives a directed codon-dependent DNA sequence evolution response in colorectal cancer cells. Science Advances. 9(1). eade9120–eade9120. 18 indexed citations
10.
Noble, Lisa B., Dennis Hsu, Siyu Chen, et al.. (2022). Two isoleucyl tRNAs that decode synonymous codons divergently regulate breast cancer metastatic growth by controlling translation of proliferation-regulating genes. Nature Cancer. 3(12). 1484–1497. 16 indexed citations
11.
Kotecha, Ritesh R., Dennis Hsu, Chung‐Han Lee, Sujata Patil, & Martin H. Voss. (2021). In silico modeling of combination systemic therapy for advanced renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 9(12). e004059–e004059. 2 indexed citations
12.
Yu, Bing, Stephen Swatkoski, Liam C. Lee, et al.. (2015). Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. Proceedings of the National Academy of Sciences. 112(14). E1724–33. 64 indexed citations
13.
Yuan, Tina L., Christof Fellmann, Chih-Shia Lee, et al.. (2014). Development of siRNA Payloads to Target KRAS -Mutant Cancer. Cancer Discovery. 4(10). 1182–1197. 93 indexed citations
14.
Dexheimer, Thomas S., Dennis Hsu, Meng‐Tzu Weng, et al.. (2014). A High-Throughput Assay for Small Molecule Destabilizers of the KRAS Oncoprotein. PLoS ONE. 9(8). e103836–e103836. 17 indexed citations
15.
Weng, Meng‐Tzu, Shu‐Chen Wei, Dennis Hsu, et al.. (2012). Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proceedings of the National Academy of Sciences. 109(52). E3659–67. 54 indexed citations
16.
Ithychanda, Sujay Subbayya, Dennis Hsu, Hanhan Li, et al.. (2010). Identification and characterization of multiple similar ligand-binding repeats in filamin.. Journal of Biological Chemistry. 285(23). 18122–18122. 4 indexed citations
17.
Ithychanda, Sujay Subbayya, Dennis Hsu, Hanhan Li, et al.. (2009). Identification and Characterization of Multiple Similar Ligand-binding Repeats in Filamin. Journal of Biological Chemistry. 284(50). 35113–35121. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kalle Ojala Breakdown of academic impact, for papers by María del Mar Maldonado Breakdown of academic impact, for papers by Frederick D. Park Breakdown of academic impact, for papers by Kristen Bisanz Breakdown of academic impact, for papers by Edison Tak‐Bun Liu Breakdown of academic impact, for papers by Francesca Miccichè Breakdown of academic impact, for papers by Weimin Hu Breakdown of academic impact, for papers by Yuliya Petrova Breakdown of academic impact, for papers by Mary Iconomou Breakdown of academic impact, for papers by Alice Boulghourjian
Rankless by CCL
2026